Rank: 111
How do comorbid pathologies (AD co-pathology, vascular burden, Lewy body/tau pathology) alter PD progression trajectories, treatment response, and clinical trial outcomes?
Approximately 30-50% of Parkinson's disease patients have significant comorbid pathologies at autopsy, including:
- Alzheimer's disease co-pathology (amyloid, tau)
- Cerebrovascular disease (white matter lesions, microinfarcts)
- Limbic vs. brainstem-predominant alpha-synuclein distribution
These mixed pathologies likely explain the heterogeneity in clinical presentation, treatment response, and progression rates in PD. However, their impact on disease course and therapeutic response is poorly understood.
- H1: AD co-pathology (positive amyloid PET) in PD predicts faster cognitive decline and reduced dopaminergic treatment response
- H2: Vascular burden correlates with axial symptoms (gait, postural instability) progression independent of dopaminergic loss
- H3: Mixed pathology patients require different therapeutic approaches (combination vs. monotherapy)
- H4: Clinical trial endpoints need pathology-informed stratification
Cohort Structure:
| Group |
N |
Criteria |
| PD only |
150 |
No significant AD/vascular co-pathology markers |
| PD + amyloid positive |
75 |
Amyloid PET positive, no clinical AD |
| PD + vascular burden |
75 |
MRI white matter hyperintensities Fazekas ≥2 |
| PD + mixed (amyloid + vascular) |
50 |
Both co-pathologies present |
| Control |
50 |
Age-matched, no neurodegenerative signs |
Assessments (annual for 5 years):
- Cognitive: MoCA, RBANS, attentional/executive batteries
- Motor: MDS-UPDRS parts I-III, gait analysis, postural sway
- Neuroimaging:
- Dopaminergic PET (FP-CIT/β-CIT)
- Amyloid PET (Florbetaben)
- Tau PET (MK-6240)
- Structural MRI (VBM, white matter)
- FDG-PET (network metabolism)
- Fluid biomarkers:
- CSF: α-syn SAA, total tau, p-tau181, Aβ42/40
- Plasma: NfL, p-tau217, GFAP
- Primary: Rate of cognitive decline (MoCA trajectory)
- Secondary: Motor progression (UPDRS III trajectory), time to falls, time to dementia
- Exploratory: Treatment response patterns, survival analysis
- Correlate antemortem imaging with neuropathological assessment
- Determine which pathology burden correlates with clinical measures
- Generate neurons from PD patients with/without co-pathology markers
- Test differential drug responses
- Stratification criteria: Define imaging/biomarker criteria for mixed pathology
- Progression models: Characterize how each comorbidity modifies PD progression
- Treatment optimization: Determine if mixed pathology patients need modified treatment approaches
- Trial design: Establish inclusion/exclusion criteria and stratification approaches
- Year 1: Enrollment complete, baseline data
- Year 2: First progression data, preliminary biomarker correlations
- Year 3: Mixed pathology groups show divergent trajectories
- Year 4: Final analysis, develop stratification algorithms
- Year 5: Publish findings, inform trial design
| Dimension |
Score |
Rationale |
| Mechanistic Impact |
9/10 |
Addresses major source of PD heterogeneity |
| Cure Proximity |
8/10 |
Enables precision therapeutic approaches |
| Feasibility |
7/10 |
Standard techniques, multi-site required |
| Cost Efficiency |
7/10 |
Large cohort but well-defined questions |
| Timeline |
6/10 |
5-year study needed |
| Cross-Disease Value |
8/10 |
Mixed pathology common in all neurodegenerative diseases |
| Biomarker Enablement |
9/10 |
Will define biomarker signatures for pathology types |
| Combinability |
7/10 |
Complements existing PD trials |
| De-risking Value |
8/10 |
Could improve clinical trial success rates |
| Novelty |
9/10 |
First comprehensive mixed pathology PD study |
Total Score: 78/100
| Item |
Cost |
| Multi-site imaging (PET/MRI) |
$2,000,000 |
| Biomarker analysis (CSF + plasma) |
$1,500,000 |
| Clinical assessments |
$600,000 |
| Data management |
$400,000 |
| Bioinformatics |
$300,000 |
| Total |
$4,800,000 |
- Irwin DJ, et al. Neuropathological and genetic correlates of survival and dementia in Parkinson's disease. Ann Neurol. 2023.
- Compta Y, et al. Lewy body and Alzheimer's disease pathologies in Parkinson's disease. Brain. 2022.
- Selikhova M, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain. 2022.